Vergleich

Recombinant Monkeypox Virus Envelope Protein H3L

ArtNr 230-30233-100
Hersteller Raybiotech
Menge 100 ug
Quantity options 100 ug 500 ug 100 ug
Kategorie
Typ Proteins Recombinant
Format Lyophilized
Applikationen WB, IP, ELISA, Dot
Specific against Monkey (Cynomolgus, Simian)
Host Human, HEK293
Konjugat/Tag HIS
Purity >95% - SDS-PAGE under reducing conditions and visualized by Coomassie blue staining
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Versandbedingung Raumtemperatur
Lieferbar
Manufacturer - Applications
Functional Assay, Protein-protein Interaction, Post-translational Modifications, ELISA, EIA, Western Blotting, Dot Blotting, Immunoprecipitation, Protein Array, etc.
Manufacturer - Category
Proteins|Recombinant Proteins|Viral Proteins
Manufacturer - Conjugate / Tag
C-terminal His-tag
Shipping Temperature
Ambient temperature
Storage Conditions
-20°C
Molecular Weight
Recombinant protein product has a calculated molecular mass of ˆ¼32 kDa. Due to the abundant glycosylation, it migrates as approximately 32-37 kDa protein bands in SDS-PAGE under DTT, beta-mercaptoethanol reducing conditions. See SDS-PAGE image below.
Gene Symbols
H3L
UNSPSC Code
12352202
Formulation
Lyophilized from a 0.2 um filtered solution in PBS (pH 7.4) with 1% mannitol and 5% trehalose
Expressed Region
Met1-Pro278
Protein Name & Synonyms
Envelope protein H3, IMV heparan-binding surface membrane protein
Format
Lyophilized powder
Purification
His-tag affinity purification by immobilized metal ion affinity chromatography (IMAC)
Concentration
Determined by BCA protein assay (lot specific)
Reconstitution
Briefly spin the vial and bring the contents to the bottom prior to opening. It is recommended to reconstitute at 0.5 - 1 mg/mL with sterile deionized water.
Endotoxin Level
<0.5 EU per µg of the protein as determined by the LAL method
SDS-PAGE Image
Figure 1. Deglycosylation analysis of purified recombinant proteins. The same amount of purified proteins were untreated (Lane 2) or treated with protein deglycosylation enzymes under native (Lane 3) or reducing (Lane 4) conditions. Deglycosylation treatment resulted in a mobility shift of the protein to produce one reduced band at the expected size, thus indicating that the untreated recombinant protein (Lane 2) was glycosylated.Lane 1: protein standard ladder (kDa).Lane 2: untreated protein.Lane 3: treated protein with deglycosylation enzymes under native conditions.Lane 4: treated protein with deglycosylation enzymes under denature conditions.

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 100 ug
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen